1. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG;Lerner;Bladder Cancer,2015
2. Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group;Kamat;J C Oncol,2016
3. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry;US Food and Drug Administration,2018
4. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
5. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021